Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MultiCell Technologies has revealed updated preclinical research results for MCT-465 and MCT-485.
Subscribe to our email newsletter
MCT-465 and MCT-485 are cancer therapeutics, which use TLR3 signaling technology.
During the trials, MCT-485 showed in vitro dose-effect cytotoxicity on several human hepatocellular carcinoma cell lines while MCT-465 showed no cytotoxicity or anti-proliferative effect.
The results will further aid mechanistic and in vivo studies exploring the safety, effectiveness and utility of MCT-465 and MCT-485 as therapeutic agents to treat hepatocellular carcinoma and other cancers.
Primary liver cancer results from Hepatitis B and Hepatitis C infection and is the most common cancer in some parts of the world with more than 1 million new cases diagnosed each year.